Alluvi, formerly BI 4744, represents a promising breakthrough in obesity therapy. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates impressive effectiveness https://loanbookmark.com/story22220221/alluvi-a-detailed-examination-into-the-drug-s-possibilities